Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Absci Corp (ABSI)

Absci Corp (ABSI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Absci to Participate in the 25th Annual Needham Virtual Healthcare Conference

VANCOUVER, Wash. and NEW YORK, April 08, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative...

ABSI : 3.23 (+1.89%)
Absci Reports Business Updates and Fourth Quarter and Full Year 2025 Financial and Operating Results

Successfully dosed first three cohorts in SAD portion of ongoing ABS-201™ HEADLINE trial; well-tolerated with favorable emerging safety data Unveiled human ex vivo data demonstrating that ABS-201...

ABSI : 3.23 (+1.89%)
Absci Launches ABS-201 Endometriosis Advisory Board with Leading Experts from Yale, UCSF, Duke, and the Mayo Clinic

VANCOUVER, Wash. and NEW YORK, March 24, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative...

ABSI : 3.23 (+1.89%)
Absci Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

VANCOUVER, Wash. and NEW YORK, March 06, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative...

ABSI : 3.23 (+1.89%)
Absci Strengthens Clinical Leadership with Appointment of Ransi Somaratne, M.D., FACC, MBA as Chief Medical Officer

Former Vertex executive to spearhead the clinical development of Absci’s expanding AI-designed therapeutics pipeline Chief Innovation Officer Andreas Busch to retire March 31, 2026 and will continue...

ABSI : 3.23 (+1.89%)
Absci to Report Business Updates and Fourth Quarter and Full Year 2025 Financial and Operating Results on March 24, 2026

VANCOUVER, Wash. and NEW YORK, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative...

ABSI : 3.23 (+1.89%)
Absci to Participate in Upcoming Investor Conferences

VANCOUVER, Wash. and NEW YORK, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics with generative AI, today...

ABSI : 3.23 (+1.89%)
Medical Breakthroughs: 5 AI Innovators Redefining What's Possible

Issued on behalf of VentriPoint Diagnostics Ltd. VANCOUVER – Baystreet.ca News Commentary – The healthcare AI market reached $21.66 billion in 2025 and analysts now project growth to $110.61...

CBLL : 20.74 (+1.02%)
ONMD : 0.8867 (+0.53%)
VPT.VN : 0.100 (unch)
LNAI : 0.3040 (-5.85%)
ABSI : 3.23 (+1.89%)
VPTDF : 0.0770 (+8.45%)
Absci to Participate in the 44th Annual J.P. Morgan Healthcare Conference

VANCOUVER, Wash. and NEW YORK, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics with generative AI, today...

ABSI : 3.23 (+1.89%)

Barchart Exclusives

As Amazon Pours Another $25B into Data Centers, Buy This 1 High-Yield Data Center Dividend Stock
Amazon’s new 25 billion dollar data‑center push underscores why American Tower’s tower network and CoreSite data‑center arm are valuable, giving investors a nearly 4% yield, discounted valuation, and direct exposure to growing cloud and AI traffic without owning a cyclical chip or hyperscaler stock. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.